2C-CP

2C-CP, or 2C-cP, also known as 4-cyclopropyl-2,5-dimethoxyphenethylamine, is a psychedelic and designer drug of the phenethylamine and 2C families. It was first synthesized by Daniel Trachsel and colleagues in 2006 and was subsequently described by them in the literature in 2013. The drug has an affinity of 95nM at the serotonin 5-HT_2A receptor and of 41nM at the 5-HT_2C receptor. 2C-CP is active at a dose of between 15 and 35mg orally with a duration of 3 to 6hours. Its effects were described as rather diffuse and undefinable, with its full effects having not yet been explored. Analogues of 2C-CP include 2C-CPE, 2C-IP, 2C-P, 2C-T-15, 2C-V, and 2C-YN, among others. The drug is a controlled substance in Canada under phenethylamine blanket-ban language. It is not an explicitly controlled substance in the United States, but it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.